Phenotype | Donor Cells | Recipient Cells | miRNA | Target Gene of miRNA | Reference |
---|---|---|---|---|---|
Induction of angiogenesis | Breast cancer cell |  | miR-210 | – | [41] |
HCC cell | EC | miR-210 | SMAD4 and STAT6 | [42] | |
Melanoma cell | Â | miR-9 | SOCS5 | [43] | |
Destruction of endothelial barriers | Breast cancer cell | EC | miR-105 | ZO-1 | [44] |
Breakdown of blood-brain barrier | Breast cancer cell | EC | miR-181c | PDPK1 | [45] |
Treg expansion | Lewis lung carcinoma | CD4 + T cell | miR-214 | PTEN | [49] |
Promotion of inflammation | Lung cancer cell | Macrophage | miR-21 and -29a | TLR | [50] |
Promoting invasion | TAM | Breast cancer cell | miR-233 | Mef2s | [51] |
TAM transition | Colorectal cancer | Monocyte | miR-203 | – | [52] |
Dysfunction of DC | Pancreatic cancer | DC | miR-203 | TLR4 | [53] |
Immune tolerance of DC | Pancreatic cancer | DC | miR-212 | RFXAP | [54] |
Up-regulation matrix metalloproteinases | Pancreatic adenocarcinoma | Fibroblast | miR-494 and − 542-3p | Cadherin-17, MAL and TRAF4 | [57] |
CAF transition | HCC cell | Fibroblast | miR-1247-3p | B4GALT3 | [59] |
Induction of EMT | CAF | Prostate cancer cell | miR-409 | RSU1 and STAG2 | [60] |
Breast cancer cell | miR-21, −278e, and − 143 | – | [61] | ||
Inhibition of apoptosis and induction of drug resistance | CAF | Ovarian cancer cell | miR-21 | APAF1 | [62] |
Reduction of glucose uptake | Breast cancer cell | Fibroblast | miR-122 | Pyruvate kinase | [63] |
Suppression of proliferation | Bone stromal cell | Breast cancer cell | miR-127, −197, −222 and − 223 | CXCL12 | [64] |
Induction of dormancy | BM-MSC | Breast cancer cell | miR-23b | MARCKS | [65] |
Induction of dormancy and drug resistance | BM-MSC | Breast cancer cell | miR-222 and − 223 | – | [66] |